



Media Contact:

Dan McFadden

(425) 836-3103

dmcfadden@oculusis.com

PHARMACEUTICAL VETERAN MICHAEL WOKASCH JOINS OCULUS INNOVATIVE SCIENCES AS CHIEF OPERATING OFFICER

PETALUMA, CA-- (July 11, 2006)— Oculus Innovative Sciences, Inc., announced today that Michael Wokasch has joined the company as chief operating officer. Mr. Wokasch has more than twenty years of experience in the healthcare industry, most recently as senior vice president of commercial operations for the biopharmaceuticals division of Chiron Corporation. He has held marketing and sales positions at Merck & Co., Miles Pharmaceuticals (now Bayer), and Abbott Laboratories; and senior management positions at Impax Laboratories, Aurora BioSciences, and Gala Design. He received his bachelor of science degree from the University of Minnesota, college of pharmacy.

Mr. Wokasch will assume responsibility for global operations including the company's manufacturing facilities in the United States, Mexico, and The Netherlands, product development, and sales and marketing.

About Oculus

Oculus Innovative Sciences, Inc. is a medical technology company focused on the development, manufacture and marketing of a family of products intended to control infection in acute and chronic wounds. The company's platform technology, called Microcyn[®], is a non-toxic, super-oxidized, water-based solution that is designed to eliminate a wide range of bacteria, viruses, fungi and spores.

Oculus' principal operations are in Petaluma, California, and it conducts business in Europe and Latin America through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V.